The ARFGEF1 Knockout HT29 Polyclonal Cells product provides a mixed population of HT29 human colorectal adenocarcinoma cells carrying CRISPR/Cas9-induced disruptions in the ARFGEF1 gene. This polyclonal knockout approach yields a heterogeneous loss-of-function model that mitigates the drawbacks of clonal selection, enabling robust functional studies across diverse genetic backgrounds.
Originally derived from a human colorectal adenocarcinoma, the HT29 cell line displays epithelial morphology and is extensively utilized as an intestinal epithelial model in cancer and drug absorption research. These cells retain the ability to differentiate and establish polarity, offering a physiologically relevant system for probing vesicle trafficking, drug transporter expression, and tumor cell biology.
ARFGEF1, also known as brefeldin A-inhibited guanine nucleotide-exchange protein 1 (BIG1), encodes a guanine nucleotide exchange factor that activates ADP-ribosylation factors (ARFs), primarily ARF1, ARF3, ARF5, and ARF6, by facilitating GDP-to-GTP exchange. Its enzymatic activity is regulated by upstream inputs from cAMP/PKA, epidermal growth factor receptor (EGFR), and phosphoinositides, and it orchestrates downstream recruitment of coatomer (COPI) and clathrin adaptor complexes (AP-1, AP-3) to Golgi and endosomal membranes. ARFGEF1 interacts with GOLPH3, myosin IXb (MYO9B), protein phosphatase 1 (PP1), and filamin A (FLNA) to coordinate vesicle budding, cargo sorting, and actin cytoskeleton remodeling, processes essential for maintaining intracellular trafficking, receptor recycling, and cell polarity.
Within the colorectal adenocarcinoma context of HT29 cells, loss of ARFGEF1 disrupts Golgi apparatus integrity and vesicle-mediated transport, impairing polarized secretion and the surface expression of adhesion molecules and growth factor receptors. This model is valuable for deciphering how ARF-dependent membrane trafficking contributes to colorectal cancer cell migration, invasion, and metastasis, and for evaluating the impact on drug transporter localization in an intestinal epithelial tumor setting. Moreover, the polyclonal nature allows observation of functional effects over a range of knockout efficiencies, better reflecting the heterogeneity found in tumor populations.
Researchers can employ this product for Western blotting and RT-qPCR to confirm ARFGEF1 depletion, immunofluorescence microscopy with Golgi markers such as GM130 to assess organelle morphology, and functional assays including transferrin uptake to measure endocytic recycling and transwell migration to evaluate motility. Additional applications encompass cell viability assessments to determine growth effects and RNA-seq to profile transcriptome-wide changes. This polyclonal knockout cell population is ideal for preliminary genetic screens, characterization of ARFGEF1-dependent pathways, and generation of mixed knockout models for tumor biology studies. For more information, please contact Ascent Research.
